Eledon Pharmaceuticals Statistics
Total Valuation
ELDN has a market cap or net worth of $103.97 million. The enterprise value is $61.39 million.
| Market Cap | 103.97M |
| Enterprise Value | 61.39M |
Important Dates
The next estimated earnings date is Thursday, August 8, 2024, before market open.
| Earnings Date | Aug 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ELDN has 38.51 million shares outstanding. The number of shares has increased by 109.92% in one year.
| Shares Outstanding | 38.51M |
| Shares Change (YoY) | +109.92% |
| Shares Change (QoQ) | +21.81% |
| Owned by Insiders (%) | 3.51% |
| Owned by Institutions (%) | 30.40% |
| Float | 28.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 2.19 |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.39 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.30, with a Debt / Equity ratio of 0.00.
| Current Ratio | 11.30 |
| Quick Ratio | n/a |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -45.60% and return on invested capital (ROIC) is -56.93%.
| Return on Equity (ROE) | -45.60% |
| Return on Assets (ROA) | -42.80% |
| Return on Capital (ROIC) | -56.93% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.99M |
| Employee Count | 20 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +97.08% in the last 52 weeks. The beta is 0.91, so ELDN's price volatility has been similar to the market average.
| Beta (5Y) | 0.91 |
| 52-Week Price Change | +97.08% |
| 50-Day Moving Average | 2.67 |
| 200-Day Moving Average | 1.91 |
| Relative Strength Index (RSI) | 53.80 |
| Average Volume (20 Days) | 109,072 |
Short Selling Information
The latest short interest is 170,622, so 0.44% of the outstanding shares have been sold short.
| Short Interest | 170,622 |
| Short Previous Month | 52,380 |
| Short % of Shares Out | 0.44% |
| Short % of Float | 0.61% |
| Short Ratio (days to cover) | 1.01 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -42.76M |
| Pretax Income | -39.85M |
| Net Income | -39.85M |
| EBITDA | -39.47M |
| EBIT | -39.85M |
| Earnings Per Share (EPS) | -$1.38 |
Balance Sheet
The company has $42.86 million in cash and $284,000 in debt, giving a net cash position of $42.58 million or $1.11 per share.
| Cash & Cash Equivalents | 42.86M |
| Total Debt | 284,000 |
| Net Cash | 42.58M |
| Net Cash Per Share | $1.11 |
| Equity (Book Value) | 74.82M |
| Book Value Per Share | 1.94 |
| Working Capital | 43.73M |
Cash Flow
| Operating Cash Flow | -38.34M |
| Capital Expenditures | n/a |
| Free Cash Flow | -38.34M |
| FCF Per Share | -$1.28 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ELDN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -109.92% |
| Shareholder Yield | -109.92% |
| Earnings Yield | -38.33% |
| FCF Yield | -36.88% |
Analyst Forecast
The average price target for ELDN is $11.67, which is 332.22% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $11.67 |
| Price Target Difference | 332.22% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -12.60% |
Stock Splits
The last stock split was on October 5, 2020. It was a reverse split with a ratio of 1:18.
| Last Split Date | Oct 5, 2020 |
| Split Type | Reverse |
| Split Ratio | 1:18 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |